LGND
NASDAQLigand Pharmaceuticals Incorporated
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$237.54+28.61 (+13.70%)
2026-03-042026-06-05
News · 26 weeks57-72%
2025-12-142026-06-07
Mix3690d
- Insider12(33%)
- SEC Filings12(33%)
- Other8(22%)
- Earnings3(8%)
- Analyst1(3%)
Latest news
25 items- INSIDERCLO & Secretary Reardon Andrew sold $1,135,316 worth of shares (5,000 units at $227.06) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERChief Financial Officer Espinoza Octavio exercised 1,736 shares at a strike of $57.58, increasing direct ownership by 7% to 27,679 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- PRLigand to Participate in June Investor ConferencesJUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference. Management will participate in one-on-one meetings with investors on June 3, 2026 in Boston.Goldman Sachs 47th Annual Global Healthcare Conference. Management will participate in a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami followed by one-on-one meetings with investors. Investors interested in arranging one-on-one meetings should contact their Stifel or Goldman Sachs representative. About Ligand PharmaceuticalsLigand
- SECSEC Form DEFA14A filed by Ligand Pharmaceuticals IncorporatedDEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECSEC Form 8-K filed by Ligand Pharmaceuticals Incorporated8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- INSIDERDirector Kozarich John W sold $563,080 worth of shares (2,501 units at $225.14) as part of a pre-agreed trading plan and exercised 2,034 shares at a strike of $69.51, decreasing direct ownership by 1% to 41,786 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECSEC Form 144 filed by Ligand Pharmaceuticals Incorporated144 - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
- PROrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesOrchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing application submission to FDA and global regulatory agencies, assuming primary endpoints are met FDA granted a second Breakthrough Device Designation ("BDD") for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemakerVirtue Trial sites progressing with site activation and patient enrollment acceleration continuing t
- SECSEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Reports First Quarter 2026 Financial ResultsFirst quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al
- PROrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed's future revenue as well as equityFunding supports continued execution of Orchestra BioMed's pivotal trials for Atrioventricular Interval Modulation Therapy ("AVIM Therapy") and Virtue Sirolimus AngioInfusion Balloon ("Virtue SAB") This payment, together with a $20 million investment from Medtronic (NYSE:MDT) announced separately, represents a total of $35 million in fresh strategic capital received on May 1, 2026 under previously disclosed agreements NEW HOPE, Pa., Ma
- PRLigand to Participate in May Investor ConferencesJUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual): Ligand CEO Todd Davis and Wes Kaupinen, president and CEO of Ligand portfolio company Palvella Therapeutics, will participate in a fireside chat at 9:30 a.m. ET on May 6, 2026.Bank of America Healthcare Conference (Las Vegas): Management will participate in a fireside chat at 4:20 p.m. PT on May 12, 2026 and be available for one-on-one meetings on May 12, 2026 and May 13, 2026.CJS Securities Spring 1x1 Conference (Virtual): Mana
- INSIDERCLO & Secretary Reardon Andrew exercised 5,000 shares at a strike of $52.27 and sold $1,156,556 worth of shares (5,000 units at $231.31) as part of a pre-agreed trading plan (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECSEC Form SCHEDULE 13D filed by Ligand Pharmaceuticals IncorporatedSCHEDULE 13D - LIGAND PHARMACEUTICALS INC (0000886163) (Filed by)
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECSEC Form DEFA14A filed by Ligand Pharmaceuticals IncorporatedDEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECSEC Form DEFA14A filed by Ligand Pharmaceuticals IncorporatedDEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECSEC Form 8-K filed by Ligand Pharmaceuticals Incorporated8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorTransaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate
- PRLigand to Report First Quarter 2026 Financial Results on May 7, 2026JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090 Webcast: Live and replay webcasts of the call are available here. About LigandLigand is a
- SECSEC Form DEFA14A filed by Ligand Pharmaceuticals IncorporatedDEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECSEC Form DEF 14A filed by Ligand Pharmaceuticals IncorporatedDEF 14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGSFILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS,
- INSIDERSEC Form 4 filed by Kozarich John W4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
LGND FAQ
6 questionsWhat does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled...Where does LGND stock trade?
Ligand Pharmaceuticals Incorporated (LGND) is listed on NASDAQ.What sector and industry is LGND in?
Ligand Pharmaceuticals Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LGND?
Ligand Pharmaceuticals Incorporated has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-03-11.What companies are similar to LGND?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LGND side-by-side with any of them on Quantisnow.How can I track LGND on Quantisnow?
Quantisnow aggregates Ligand Pharmaceuticals Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGND to receive live email and push alerts on every new disclosure.